Marksans Pharma has announced that its wholly owned UK subsidiary, Relonchem Limited, has received marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for two new formulations of Mefenamic Acid. The approvals cover the 250 mg and 500 mg film-coated tablet variants, expanding the company’s footprint in the UK pharmaceutical market.
Mefenamic Acid is widely used for the treatment of pain and inflammation, and the newly approved products are expected to strengthen Marksans Pharma’s analgesic portfolio in the region. With this development, the company continues to build its presence in key regulated markets, further supporting its strategy of delivering high-quality, affordable medications globally.
The authorization marks another step forward for Marksans Pharma as it focuses on expanding its product pipeline and enhancing its international reach through its subsidiary Relonchem.
